Search jobs 09-Mar-2021 Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT
®.
COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 8
th, 2021 – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.
COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.
Oxford Immunotec has filed for emergency use authorization for its T-SPOT.COVID test, which detects T cell immune responses to COVID-19, the Marlborough and United Kingdom-based company announced on Thursday.
(2)
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company ), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.
COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.
Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infection. Antibodies are not always produced in response to SARS-CoV-2 infection, or may be delayed
1,2. Antibodies can also wane quickly after infection
/PRNewswire/ Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the.